Search Results - "Till, Brian"

Stop the Bleed: Airway Hemorrhage After Pulmonary Thromboendarterectomy? by Till, Brian M., Tchantchaleishvili, Vakhtang, Rajagopal, Keshava

Get full text

Prospects for chimeric antigen receptor (CAR) gamma delta T cells: A potential game changer for adoptive T cell cancer immunotherapy by Mirzaei, Hamid Reza, Mirzaei, Hamed, Lee, Sang Yun, Hadjati, Jamshid, Till, Brian G

“…Excitement is growing for therapies that harness the power of patients' immune systems to combat their diseases. One approach to immunotherapy involves…”
Get full text

Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells by Wang, Zibing, Till, Brian, Gao, Quanli

“…Immunotherapy has shown great promise in the fight against cancer, as evidenced by the clinical efficacy of chimeric antigen receptor T cells in hematologic…”
Get full text

The Creative Knife: Does Interference Dull the Edge of Creativity Effectiveness? by Lehnert, Kevin, Till, Brian D., Coble, Kyle, Arnold, Mark J.

“…It is no secret that creativity is an important component of advertising. It can enhance attention, facilitate recall, and drive emotional responses. However,…”
Get full text

Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma by Budde, Lihua E, Berger, Carolina, Lin, Yukang, Wang, Jinjuan, Lin, Xubin, Frayo, Shani E, Brouns, Shaunda A, Spencer, David M, Till, Brian G, Jensen, Michael C, Riddell, Stanley R, Press, Oliver W

“…Modification of T cells with chimeric antigen receptors (CAR) has emerged as a promising treatment modality for human malignancies. Integration of…”
Get full text

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy by Hay, Kevin A., Gauthier, Jordan, Hirayama, Alexandre V., Voutsinas, Jenna M., Wu, Qian, Li, Daniel, Gooley, Ted A., Cherian, Sindhu, Chen, Xueyan, Pender, Barbara S., Hawkins, Reed M., Vakil, Aesha, Steinmetz, Rachel N., Schoch, Gary, Chapuis, Aude G., Till, Brian G., Kiem, Hans-Peter, Ramos, Jorge D., Shadman, Mazyar, Cassaday, Ryan D., Acharya, Utkarsh H., Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.

“…Autologous T cells engineered to express a CD19-specific chimeric antigen receptor (CAR) have produced impressive minimal residual disease–negative…”
Get full text

Prospects for chimeric antigen receptor (CAR) γδ T cells: a potential game changer for adoptive T cell cancer immunotherapy by Mirzaei, Hamid Reza, Mirzaei, Hamed, Lee, Sang Yun, Hadjati, Jamshid, Till, Brian G

“…Highlights • γδ T cells are unique and crucial cell population in mucosal epithelial microenvironment. • Utilizing CAR γδ T would be a promising…”
Get full text

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells by Hirayama, Alexandre V., Gauthier, Jordan, Hay, Kevin A., Voutsinas, Jenna M., Wu, Qian, Gooley, Ted, Li, Daniel, Cherian, Sindhu, Chen, Xueyan, Pender, Barbara S., Hawkins, Reed M., Vakil, Aesha, Steinmetz, Rachel N., Acharya, Utkarsh H., Cassaday, Ryan D., Chapuis, Aude G., Dhawale, Tejaswini M., Hendrie, Paul C., Kiem, Hans-Peter, Lynch, Ryan C., Ramos, Jorge, Shadman, Mazyar, Till, Brian G., Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.

“…Factors associated with durable remission after CD19 chimeric antigen receptor (CAR)-modified T-cell immunotherapy for aggressive B-cell non-Hodgkin lymphoma…”
Get full text

Predictive and therapeutic biomarkers in chimeric antigen receptor T‐cell therapy: A clinical perspective by Mirzaei, Hamid Reza, Mirzaei, Hamed, Namdar, Afshin, Rahmati, Majid, Till, Brian G., Hadjati, Jamshid

“…The adoptive transfer of genetically engineered T cells modified to express a chimeric antigen receptor (CAR) has shown remarkable activity and induces…”
Get full text

Scalable Manufacturing of CAR T cells for Cancer Immunotherapy by Abou-El-Enein, Mohamed, Elsallab, Magdi, Feldman, Steven A, Fesnak, Andrew D, Heslop, Helen E, Marks, Peter, Till, Brian G, Bauer, Gerhard, Savoldo, Barbara

“…As of April 2021, there are five commercially available chimeric antigen receptor (CAR) T cell therapies for hematological malignancies. With the current…”
Get full text

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies by Gauthier, Jordan, Bezerra, Evandro D., Hirayama, Alexandre V., Fiorenza, Salvatore, Sheih, Alyssa, Chou, Cassie K., Kimble, Erik L., Pender, Barbara S., Hawkins, Reed M., Vakil, Aesha, Phi, Tinh-Doan, Steinmetz, Rachel N., Jamieson, Abby W., Bar, Merav, Cassaday, Ryan D., Chapuis, Aude G., Cowan, Andrew J., Green, Damian J., Kiem, Hans-Peter, Milano, Filippo, Shadman, Mazyar, Till, Brian G., Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.

“…CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T-cell therapy has shown significant efficacy for relapsed or refractory (R/R) B-cell…”
Get full text

Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma by Till, Brian G.

“…Opinion statement Maintenance therapy has evolved as a strategy to prolong remissions in patients with diffuse large B cell lymphoma (DLBCL) or mantle cell…”
Get full text

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results by Till, Brian G., Jensen, Michael C., Wang, Jinjuan, Qian, Xiaojun, Gopal, Ajay K., Maloney, David G., Lindgren, Catherine G., Lin, Yukang, Pagel, John M., Budde, Lihua E., Raubitschek, Andrew, Forman, Stephen J., Greenberg, Philip D., Riddell, Stanley R., Press, Oliver W.

“…Cellular immune responses have the potential to elicit dramatic and sustained clinical remissions in lymphoma patients. Recent clinical trial data demonstrate…”
Get full text

Creativity, attention and the memory for brands: an outdoor advertising field study by Wilson, Rick T., Baack, Daniel W., Till, Brian D.

“…This study investigates whether creativity is sufficient by itself to attract attention to the ad space or whether the ad must also be conspicuous. Attention…”
Get full text

Advertising Creativity: The Role of Divergence Versus Meaningfulness by Lehnert, Kevin, Till, Brian D., Ospina, José Miguel

“…Creativity is seen as an essential component of advertising and is continuing to attract research interest. While there is widespread agreement on the value of…”
Get full text

Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy by Smith, Stephen D., Till, Brian G., Shadman, Mazyar S., Lynch, Ryan C., Cowan, Andrew J., Wu, Qian V., Voutsinas, Jenna, Rasmussen, Heather A., Blue, Katherine, Ujjani, Chaitra S., Shustov, Andrei, Cassaday, Ryan D., Fromm, Jonathan R., Gopal, Ajay K.

“…Summary Tumor programmed death‐ligand 1 (PD‐L1) expression in diffuse large B‐cell lymphoma (DLBCL) is associated with inferior outcomes. The first‐line…”
Get full text

Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients by Yuan, Shumin, Peng, Ling, Liu, Yuqing, Till, Brian G., Yan, Xiang, Zhang, Jie, Zhu, Liping, Wang, Huijuan, Zhang, Shaokai, Li, Hongle, Gao, Quanli, Wang, Zibing

“…Background Anti-angiogenic drugs increase anti-tumor efficacy of immune checkpoint inhibitors (ICIs). However, the optimal dose of anti-angiogenic drugs…”
Get full text

Pretreatment Peripheral B Cells Are Associated With Tumor Response to Anti-PD-1-Based Immunotherapy by Yuan, Shumin, Liu, Yuqing, Till, Brian, Song, Yongping, Wang, Zibing

“…Identification of reliable biomarkers to predict efficacy of immune checkpoint inhibitors and to monitor relapse in cancer patients receiving this therapy…”
Get full text

Outcomes of patients with large B‐cell lymphomas and progressive disease following CD19‐specific CAR T‐cell therapy by Chow, Victor A., Gopal, Ajay K., Maloney, David G., Turtle, Cameron J., Smith, Stephen D., Ujjani, Chaitra S., Shadman, Mazyar, Cassaday, Ryan D., Till, Brian G., Tseng, Yolanda D., Warren, Edus H., Shustov, Andrei R., Menon, Manoj P., Bhark, Sandra, Acharya, Utkarsh H., Mullane, Erin, Hannan, Lindsay M., Voutsinas, Jenna M., Gooley, Ted A., Lynch, Ryan C.

Get full text

Construction and functional characterization of a fully human anti‐CD19 chimeric antigen receptor (huCAR)‐expressing primary human T cells by Mirzaei, Hamid Reza, Jamali, Arezoo, Jafarzadeh, Leila, Masoumi, Elham, Alishah, Khadijeh, Fallah Mehrjardi, Keyvan, Emami, Seyed Amir Hossein, Noorbakhsh, Farshid, Till, Brian G., Hadjati, Jamshid

“…Although remarkable results have been attained by adoptively transferring T cells expressing fully murine and/or humanized anti‐CD19 chimeric antigen receptors…”
Get full text